Save this content for laterSave this content on your device for later, even while offline Sign in with FacebookSign in with your Facebook account Close

Indecision from FDA puzzles patients

By: Joe Graedon and Teresa Graedon King Features Syndicate
June 25, 2013
0

The Food and Drug Administration is charged with protecting the public health, but some of its recent actions raise serious questions about drug safety.

One puzzle is its shifting stance on the diabetes drug rosiglitazone (Avandia). Several years ago, Avandia was marketed aggressively and widely prescribed. In its heyday, it earned more than $3 billion a year, making it the most successful diabetes drug of all time. Then cardiologist Steve Nissen, M.D., published an article in the New England Journal of Medicine (June 14, 2007) revealing a 43 percent increased risk of heart attack among patients taking Avandia.

Avandia immediately became a highly controversial medication. According to Nissen, the company and the FDA were aware of potential cardiovascular problems associated with Avandia before he published his critical article. The FDA eventually restricted use of the drug, which was banned outright in Europe.

The agency and the manufacturer, GSK, requested a reanalysis of a European study of Avandia. The researchers concluded that there was no increased risk of heart attacks after all. The FDA convened an advisory committee to hear this report, and this panel suggested that the restrictions on Avandia be loosened. Has the FDA lost sight of the reported suffering that has been associated with this drug?

One reader wrote:

"I have been a Type 2 diabetic since 2001 and have been on metformin since 2002. Along with diet and daily exercise, it has managed my condition very nicely.

"In 2005, my 44-year-old son was also diagnosed with Type 2 diabetes. His health needs were met by his company's health plan. For some reason he was put on Avandia.

"He had a massive heart attack and died Oct. 13, 2006, at age 45. I asked his wife what his medications were, and she said he was taking Avandia. Why he was put on that drug immediately upon being diagnosed I will never understand. A good physician usually tries the trusted drugs that have been on the market for a while. I believe that my son was one of the first guinea pigs to die because of Avandia."

It can take years or even decades for the FDA to discover serious side effects of commonly prescribed medications. The pain reliever propoxyphene (Darvon, Darvocet), the weight-loss medicine sibutramine (Meridia) and the arthritis drug rofecoxib (Vioxx) were taken by millions of people before it was discovered that each increased the risk of heart attacks or strokes. They eventually were pulled off the market.

It remains to be seen whether the FDA will ease restrictions on Avandia. If the FDA wants to keep the confidence of the American people, it must put the public health uppermost in its deliberations.

-

Joe Graedon is a pharmacologist. Teresa Graedon holds a doctorate in medical anthropology and is a nutrition expert.

Register to the Colorado Springs Gazette
Incognito Mode Your browser is in Incognito mode

You vanished!

We welcome you to read all of our stories by signing into your account. If you don't have a subscription, please subscribe today for daily award winning journalism.

Register to the Colorado Springs Gazette
Register to the Colorado Springs Gazette
Subscribe to the Colorado Springs Gazette

It appears that you value local journalism. Thank you.

Subscribe today for unlimited digital access with 50% fewer ads for a faster browsing experience.

Already a Subscriber? LOGIN HERE

Subscribe to the Colorado Springs Gazette

It appears that you value local journalism. Thank you.

Subscribe today for unlimited digital access with 50% fewer ads for a faster browsing experience.

Subscribe to the Colorado Springs Gazette

Some news is free.
Exceptional journalism takes time, effort and your support.

Already a Subscriber? LOGIN HERE

articles remaining
×
Thank you for your interest in local journalism.
Gain unlimited access, 50% fewer ads and a faster browsing experience.